The partnership helps Novo capture patients who have been using compounded versions of the medicine, while allowing ...

The collaboration, set to begin on 1 July, will see Novo Nordisk team up with the telehealth company to offer Wegovy to customers. WeightWatchers will work with CenterWell Pharmacy to dispense, manage ...

Many health and wellness stocks have faced challenges in recent years as GLP-1 weight-loss drugs like Ozempic and Wegovy ...

Novo Nordisk is a global diabetes and weight loss leader with strong long-term growth prospects. Read why NVO stock is a ...

Novo Nordisk A/S (NYSE:NVO) announced on June 26 that it will collaborate with WeightWatchers to begin distributing the bestselling weight-loss medication Wegovy, beginning July 1.

WeightWatchers Clinic Members Can Access FDA-Approved Wegovy® for $299 in July, a $200 Savings Offer to Improve Access as WeightWatchers’ Trusted, Science-Backed Approach Continues to Lead the ...

WeightWatchers’ stock was surging after the company emerged from bankruptcy two months after it was announced.

Novo Nordisk plans to expand access to Wegovy through a collaboration with WeightWatchers, days after ending a partnership with telehealth firm Hims & Hers to sell the weight-loss drug. The ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say the company's cautious culture is to blame.

It wasn't so long ago that Novo Nordisk (NVO 1.02%), a Denmark-based pharmaceutical company, seemed to be firing on all cylinders. However, the past year has been challenging for the drugmaker.